Percutaneous coronary intervention versus optimal medical therapy for prevention of spontaneous myocardial infarction
Sripal Bangalore1, Seema Pursnani, Sunil Kumar
1Cardiovascular Clinical Research Center, New York University School of Medicine, Leon H. Charney Division of Cardiology, New York, NY 10016, USA. sripalbangalore@gmail.com
Circulation
|January 18, 2013
Summary
Percutaneous coronary intervention (PCI) reduces spontaneous myocardial infarction (MI) but increases procedural MI. This suggests PCI may lower mortality risk, aligning with spontaneous MI
Area of Science:
- Cardiology
- Interventional Cardiology
- Clinical Trials
Background:
- Spontaneous myocardial infarction (MI) is linked to mortality, unlike procedural MI.
- The effect of percutaneous coronary intervention (PCI) on spontaneous MI is not well-established.
Purpose of the Study:
- To determine if PCI reduces spontaneous (nonprocedural) myocardial infarction (MI).
- To assess the impact of PCI on procedural MI and overall MI rates.
Main Methods:
- A meta-analysis of 12 randomized clinical trials comparing PCI with optimal medical therapy (OMT).
- Included 37,548 patient-years of follow-up, analyzing spontaneous MI, procedural MI, and all MI outcomes.
- Used mixed-effect Poisson regression due to varying follow-up lengths.
Main Results:
- PCI significantly reduced spontaneous nonprocedural MI (IRR=0.76; 95% CI, 0.58-0.99).
- PCI increased the rate of procedural MI (IRR=4.11; 95% CI, 2.53-6.88).
- No significant difference was found in the overall risk of MI (IRR=0.96; 95% CI, 0.74-1.21).
Conclusions:
- PCI reduces spontaneous MI but carries a risk of procedural MI, with no change in overall MI rates.
- The observed trend of reduced mortality with PCI aligns with the prevention of spontaneous MI.
- Further research is required to confirm the causal relationship between PCI, spontaneous MI reduction, and mortality benefits.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...


